hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan tells Proactive's Stephen Gunnion that the company has secured its third human challenge trial contract in recent months, this time with a new European biotech client for an influenza study starting almost immediately.
Khan describes a "significant uptick" in pipeline opportunities and contract conversions, a marked improvement on the slowdown seen in 2025. Crucially, hVIVO is now signing full clinical trial agreements rather than earlier-stage deals, reducing cancellation risk and bringing revenue recognition forward.
The company has strong visibility over 2026 revenues and remains on track for high single-digit growth. As Khan puts it: "We are on target for that. But this contract also helped us to cement some of the revenue visibility going into 2027."
For more insights like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications for future updates.
#hVIVO #Biotech #ClinicalTrials #HumanChallengeTrials #Influenza #PharmaNews #BiotechInvesting #HealthcareInnovation #LifeSciences #CEOInterview #GrowthOutlook #DrugDevelopment
